zemplarDr. Reddy’s Laboratories Ltd said it launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar injection in the United States market approved by the US Food & Drug Administration (USFDA).

The Zemplar brand and generic had US sales of approximately $22.5 million for the most recent twelve months ending in July 2016 according to IMS Health.

Dr. Reddy’s Paricalcitol injection is available in 2 mog, 5mcg, and 10 mog, and is the first ANDA product launched in the US market.

Zemplar is a registered trademark of ABBVIE Inc.

Dr. Reddy’s Laboratories Ltd. is an India pharmaceutical company and offers products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

(Now you can get topic-based alerts via WhatsApp)
Read More On..